OncLive® On Air cover image

S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

OncLive® On Air

00:00

Intro

This chapter explores the FDA's recent approval of Imetalstat for treating lower-risk myelodysplastic syndromes and transfusion-dependent anemia. Insights from the Phase III EMERGE trial reveal the drug's efficacy in improving red blood cell transfusion independence for patients unresponsive to previous treatments.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app